What is the share price of Panacea Biotec Ltd (PANACEABIO) today?
The share price of PANACEABIO as on 16th July 2025 is ₹441.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Panacea Biotec Ltd (PANACEABIO) share?
The past returns of Panacea Biotec Ltd (PANACEABIO) share are- Past 1 week: 4.74%
- Past 1 month: -6.13%
- Past 3 months: -8.05%
- Past 6 months: 4.87%
- Past 1 year: 217.27%
- Past 3 years: 237.06%
- Past 5 years: 144.20%
What are the peers or stocks similar to Panacea Biotec Ltd (PANACEABIO)?
The peers or stocks similar to Panacea Biotec Ltd (PANACEABIO) include:What is the market cap of Panacea Biotec Ltd (PANACEABIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Panacea Biotec Ltd (PANACEABIO) is ₹2671.45 Cr as of 16th July 2025.What is the 52 week high and low of Panacea Biotec Ltd (PANACEABIO) share?
The 52-week high of Panacea Biotec Ltd (PANACEABIO) is ₹581.90 and the 52-week low is ₹130.What is the PE and PB ratio of Panacea Biotec Ltd (PANACEABIO) stock?
The P/E (price-to-earnings) ratio of Panacea Biotec Ltd (PANACEABIO) is -319.17. The P/B (price-to-book) ratio is 3.16.Which sector does Panacea Biotec Ltd (PANACEABIO) belong to?
Panacea Biotec Ltd (PANACEABIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Panacea Biotec Ltd (PANACEABIO) shares?
You can directly buy Panacea Biotec Ltd (PANACEABIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Panacea Biotec Ltd
PANACEABIO Share Price
PANACEABIO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PANACEABIO Performance & Key Metrics
PANACEABIO Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-316.15 | 3.16 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.80 | 6.51 | 0.80% |
PANACEABIO Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
PANACEABIO Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
PANACEABIO Forecast
PANACEABIO Forecasts
PANACEABIO
PANACEABIO
Income
Balance Sheet
Cash Flow
PANACEABIO Income Statement
PANACEABIO Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 598.59 | 600.78 | 795.34 | 574.08 | 634.86 | 2,348.41 | 614.27 | 621.00 | 615.74 | 615.74 | ||||||||||
Raw Materials | 158.42 | 197.98 | 135.06 | 190.01 | 199.02 | 311.17 | 218.29 | 212.27 | 585.00 | 585.00 | ||||||||||
Power & Fuel Cost | 30.55 | 33.52 | 34.55 | 29.74 | 30.94 | 37.82 | 31.95 | 35.95 | ||||||||||||
Employee Cost | 148.12 | 151.59 | 147.08 | 142.32 | 156.17 | 182.97 | 126.48 | 149.57 | ||||||||||||
Selling & Administrative Expenses | 86.07 | 68.92 | 94.77 | 83.69 | 75.20 | 102.87 | 70.56 | 70.78 | ||||||||||||
Operating & Other expenses | 73.74 | 57.06 | 179.67 | 88.77 | 88.30 | 39.60 | 110.63 | 110.66 | ||||||||||||
EBITDA | 101.69 | 91.71 | 204.21 | 39.55 | 85.23 | 1,673.98 | 56.36 | 41.77 | 30.74 | 30.74 | ||||||||||
Depreciation/Amortization | 67.95 | 57.28 | 54.00 | 43.22 | 45.59 | 43.78 | 39.12 | 36.71 | 34.81 | 34.81 | ||||||||||
PBIT | 33.74 | 34.43 | 150.21 | -3.67 | 39.64 | 1,630.20 | 17.24 | 5.06 | -4.07 | -4.07 | ||||||||||
Interest & Other Items | 100.93 | 100.58 | 104.83 | 173.98 | 185.34 | 180.84 | 4.44 | 3.58 | 3.88 | 3.88 | ||||||||||
PBT | -67.19 | -66.15 | 45.38 | -177.65 | -145.70 | 1,449.36 | 12.80 | 1.48 | -7.95 | -7.95 | ||||||||||
Taxes & Other Items | -12.70 | 7.84 | 7.65 | 16.61 | 1.99 | 371.04 | 46.04 | 2.65 | 0.42 | 0.50 | ||||||||||
Net Income | -54.49 | -73.99 | 37.73 | -194.26 | -147.69 | 1,078.32 | -33.24 | -1.17 | -8.37 | -8.45 | ||||||||||
EPS | -8.16 | -11.08 | 5.65 | -29.10 | -23.07 | 176.05 | -5.43 | -0.19 | -1.37 | -1.38 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PANACEABIO Company Updates
PANACEABIO Stock Peers
PANACEABIO Past Performance & Peer Comparison
PANACEABIO Past Performance & Peer Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Panacea Biotec Ltd | -319.17 | 3.16 | — |
Biocon Ltd | 51.42 | 2.06 | 0.29% |
Onesource Specialty Pharma Ltd | -1,271.04 | 57.69 | — |
Sai Life Sciences Ltd | 99.42 | 17.35 | — |
PANACEABIO Stock Price Comparison
Compare PANACEABIO with any stock or ETFPANACEABIO Holdings
PANACEABIO Shareholdings
PANACEABIO Promoter Holdings Trend
PANACEABIO Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
PANACEABIO Institutional Holdings Trend
PANACEABIO Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding History
PANACEABIO Shareholding History
smallcases containing PANACEABIO stock
smallcases containing PANACEABIO stock
Looks like this stock is not in any smallcase yet.
PANACEABIO Events
PANACEABIO Events
PANACEABIO Dividend Trend
PANACEABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
PANACEABIO Dividend Trend
PANACEABIO has not given any dividends in last 5 years
PANACEABIO Upcoming Dividends
PANACEABIO Upcoming Dividends
No upcoming dividends are available
PANACEABIO Past Dividends
PANACEABIO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2011
Dividend/Share
₹0.75
Ex DateEx Date
Sep 19, 2011
Cash Dividend
Ex DateEx DateSep 16, 2010
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2010
PANACEABIO Stock News & Opinions
PANACEABIO Stock News & Opinions
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8'C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, 'It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.' Powered by Capital Market - Live
Net Loss of Panacea Biotec reported to Rs 1.89 crore in the quarter ended March 2025 as against net loss of Rs 1.99 crore during the previous quarter ended March 2024. Sales declined 2.88% to Rs 132.53 crore in the quarter ended March 2025 as against Rs 136.46 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 8.37 crore in the year ended March 2025 as against net loss of Rs 1.17 crore during the previous year ended March 2024. Sales declined 0.01% to Rs 559.09 crore in the year ended March 2025 as against Rs 559.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales132.53136.46 -3 559.09559.17 0 OPM %-20.28-4.43 --4.63-3.59 - PBDT-19.333.95 PL -9.132.16 PL PBT-27.75-4.86 -471 -43.94-34.55 -27 NP-1.89-1.99 5 -8.37-1.17 -615 Powered by Capital Market - Live
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
Net profit of Panacea Biotec reported to Rs 4.52 crore in the quarter ended December 2024 as against net loss of Rs 2.28 crore during the previous quarter ended December 2023. Sales rose 8.63% to Rs 163.49 crore in the quarter ended December 2024 as against Rs 150.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales163.49150.50 9 OPM %4.87-0.10 - PBDT10.594.68 126 PBT1.61-4.43 LP NP4.52-2.28 LP Powered by Capital Market - Live
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
Panacea Biotec announced that the company's wholly owned subsidiary, Panacea Biotec Pharma (PBPL) has launched baby diapers and wipes under the brand name 'NikoMom'. Powered by Capital Market - Live
Panacea Biotec announced that the company's material subsidiary, Panacea Biotec Pharma (PBCL) has made further investment of US$ 9,25,000 (~Rs.7.92 crore) in its wholly owned subsidiary, Panacea Biotec Inc. (PB Inc.) subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share. Panacea Biotec Inc. being a step-down subsidiary of the company. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL. Powered by Capital Market - Live
The contract is worth $14.95 million (approximately Rs 127 crore). The said order will be executed by calendar year 2025, subject to signing of requisite amendment to the long term arrangement. The project entails supply of bOPV to UNICEF for its requirements in countries in Africa and Asia region as per the orders as may be received from time to time. Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported consolidated net loss of Rs 8.29 crore in Q2 FY24 as compared with net profit of Rs 15.70 crore reported in Q2 FY23. Net sales jumped 36.1% YoY to Rs 143.02 crore in Q2 FY24.Powered by Capital Market - Live
Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live
Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 1.41%, vs industry avg of 21.18%
Over the last 5 years, market share decreased from 6.83% to 2.8%